Compare NEULAND LABS with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NEULAND LABS NATCO PHARMA NEULAND LABS/
NATCO PHARMA
 
P/E (TTM) x 58.0 35.0 165.6% View Chart
P/BV x 4.4 5.0 88.1% View Chart
Dividend Yield % 0.1 0.7 12.2%  

Financials

 NEULAND LABS   NATCO PHARMA
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
NATCO PHARMA
Mar-19
NEULAND LABS/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs754849 88.8%   
Low Rs247557 44.4%   
Sales per share (Unadj.) Rs594.5573.8 103.6%  
Earnings per share (Unadj.) Rs12.6176.0 7.2%  
Cash flow per share (Unadj.) Rs37.0198.2 18.7%  
Dividends per share (Unadj.) Rs2.006.25 32.0%  
Dividend yield (eoy) %0.40.9 45.0%  
Book value per share (Unadj.) Rs553.4842.7 65.7%  
Shares outstanding (eoy) m12.8336.50 35.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.81.2 68.7%   
Avg P/E ratio x39.64.0 991.8%  
P/CF ratio (eoy) x13.53.5 381.2%  
Price / Book Value ratio x0.90.8 108.4%  
Dividend payout %15.83.6 445.8%   
Avg Mkt Cap Rs m6,42125,660 25.0%   
No. of employees `0001.35.0 25.9%   
Total wages/salary Rs m1,2363,559 34.7%   
Avg. sales/employee Rs Th5,949.44,225.3 140.8%   
Avg. wages/employee Rs Th963.8718.0 134.2%   
Avg. net profit/employee Rs Th126.41,295.9 9.8%   
INCOME DATA
Net Sales Rs m7,62720,945 36.4%  
Other income Rs m391,302 3.0%   
Total revenues Rs m7,66622,247 34.5%   
Gross profit Rs m1,0197,948 12.8%  
Depreciation Rs m313810 38.6%   
Interest Rs m216193 111.8%   
Profit before tax Rs m5298,247 6.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3671,823 20.1%   
Profit after tax Rs m1626,424 2.5%  
Gross profit margin %13.437.9 35.2%  
Effective tax rate %69.422.1 313.8%   
Net profit margin %2.130.7 6.9%  
BALANCE SHEET DATA
Current assets Rs m5,15223,472 21.9%   
Current liabilities Rs m3,5767,287 49.1%   
Net working cap to sales %20.777.3 26.7%  
Current ratio x1.43.2 44.7%  
Inventory Days Days10592 114.0%  
Debtors Days Days9188 103.0%  
Net fixed assets Rs m3,96918,648 21.3%   
Share capital Rs m129365 35.3%   
"Free" reserves Rs m6,97134,525 20.2%   
Net worth Rs m7,10030,760 23.1%   
Long term debt Rs m7740-   
Total assets Rs m12,31043,031 28.6%  
Interest coverage x3.543.7 7.9%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.5 127.3%   
Return on assets %3.115.4 20.0%  
Return on equity %2.320.9 10.9%  
Return on capital %9.527.4 34.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,18711,536 45.0%   
Fx outflow Rs m1,5932,939 54.2%   
Net fx Rs m3,5948,597 41.8%   
CASH FLOW
From Operations Rs m5736,688 8.6%  
From Investments Rs m-487-6,122 8.0%  
From Financial Activity Rs m-55-509 10.8%  
Net Cashflow Rs m3366 49.4%  

Share Holding

Indian Promoters % 36.3 52.0 69.7%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 63.7 7.8 812.9%  
FIIs % 0.0 16.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 63.7 26.0 245.1%  
Shareholders   12,705 25,395 50.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NEULAND LABS With:   TORRENT PHARMA  ALKEM LABORATORIES  ELDER PHARMA  PFIZER  ALEMBIC PHARMA  

Compare NEULAND LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

NEULAND LABS SHARE PRICE


Apr 16, 2021 (Close)

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NEULAND LABS - WYETH COMPARISON

COMPARE NEULAND LABS WITH

MARKET STATS